SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Aliment Pharmacol Ther. 2023;58(3):322-333.

Low-quality muscle mass rather than normal-quality muscle mass determines fibrosis progression in biopsy-proven NAFLD.

, , , , , , , , , , , ,

제1저자 이윤규, 구보경 · 교신저자 김원

PMID 37248793 DOI 10.1111/apt.17601 IF 6.8 소화기내과
소속 (5)
  1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  2. Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea.
  3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea.
  4. Department of Radiology, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea.
  5. Department of Pathology, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea.

Abstract

BACKGROUND AND AIMS Sarcopaenia is associated with advanced nonalcoholic fatty liver disease (NAFLD). However, the impact of the muscle mass categorised by muscle quality on fibrosis progression remains unclear.

METHODS A total of 292 patients with biopsy-proven NAFLD who underwent serial vibration-controlled transient elastography assessments at least 1 year from baseline were selected. The skeletal muscle area (SMA) was determined on abdominal computed tomography (CT) at the third lumbar vertebra level and categorised to normal-attenuation muscle area (NAMA), low-attenuation muscle area (LAMA) and intermuscular adipose tissue (IMAT) using a muscle quality map. These SMAs were normalised by the height squared to obtain the skeletal muscle index (SMI).

RESULTS At baseline, as the histological fibrosis stage increased, SMINAMA decreased and SMILAMA increased (p for trend = 0.014 and p for trend <0.001, respectively), which was not significant after adjustment for age, sex and obesity. During a median follow-up of 41 months, fibrosis progression was detected in 48 out of 292 patients, and higher SMILAMA quartiles independently increased the risk of fibrosis progression in a dose-dependent manner (hazard ratio [HR] per quartile: 1.41; 95% confidence interval [CI], 1.04-1.91). The highest quartile of SMILAMA increased the risk of fibrosis progression by 3.25 times compared to the lowest quartile of SMILAMA (95% CI, 1.18-8.90). SMINAMA quartiles were not associated with the risk of fibrosis progression.

CONCLUSION Increased low-quality muscle mass, but not decreased normal-quality muscle mass, as assessed by a muscle quality map in CT, predicts fibrosis progression in patients with NAFLD.

© 2023 John Wiley & Sons Ltd.

Comment · 정정

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
Alimentary pharmacology & therapeutics · eISSN 1365-2036
전자 출판
2023-05-29
MeSH
Humans · Non-alcoholic Fatty Liver Disease* / pathology · Muscle, Skeletal / diagnostic imaging / pathology · Liver Cirrhosis / diagnostic imaging / complications · Obesity / complications · Biopsy
연구비
Korea Centers for Disease Control and Prevention 2022ER090200 · Korea Health Industry Development Institute HI21C0538 · National Research Foundation of Korea 2021M3A9E4021818 · National Research Foundation of Korea 2021R1A2C2005820
참고문헌
43편